Return to search results.
Complete title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
|Research Study Number||20122073|
|Principal Investigator||William Harris|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Gastrointestinal Cancer; Liver Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.